The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, multicenter and parallel-group study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Data were analysed from a 156-week extension of a 104-week multicentre, randomised, double-blind, parallel-group trial.

Changes in metabolic parameters - glucose, insulin, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol - were recorded.

Alterations in weight, body mass index standard deviation score (BMI SDS) and vital signs were also evaluated.

What Was Measured

The subject headings attached to it are Asian People, Blood Glucose, Body Height, Growth Disorders, Human Growth Hormone, Infant, Small for Gestational Age and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.